Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis

International Journal of Cancer

Volumn 100, Issue 5, 2002, Pages 542-548

  Lecomte, Thierry ^a,b   Berger, Anne ^b   Zinzindohoué, Franck ^b   Micard, Stéphanie ^a   Landi, Bruno ^b   Blons, Hélène ^a   Beaune, Philippe ^a   Cugnenc, Paul Henri ^b   Laurent Puig, Pierre ^a,b  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Colorectal cancer; Free circulating tumor associated DNA; Plasma; Prognosis

Indexed keywords

CELL DNA;

ADULT; AGED; ALLELE; ARTICLE; CANCER GENETICS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; DNA DAMAGE; DNA DETERMINATION; DNA METHYLATION; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SURVIVAL RATE; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0037055554     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10526     Document Type: Article

References (47)

1. Some recent developments in the epidemiology of colorectal cancer
2. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
3. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
4. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
5. Genetic alterations during colorectal-tumor development
6. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
7. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors
8. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors
9. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA)
10. Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma
11. Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA)
12. Identification of p53 gene mutations in bladder cancers and urine samples
13. Microsatellite alterations in plasma DNA of small cell lung cancer patients
14. Microsatellite alterations in serum DNA of head and neck cancer patients
15. c-Ki-ras mutations in peripheral blood of pancreatic cancer patients. A marker for early tumor metastasis
16. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
17. Detection of tumour DNA in serum of colorectal cancer patients
18. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer
19. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma
20. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: Correlation with clinicopathological features
21. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients
22. Molecular detection of genetic alterations in the serum of colorectal cancer patients
23. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients
24. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients
25. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients
26. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients
27. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: A prospect for early diagnosis
28. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients
29. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia
30. Microsatellite alterations plasma DNA of primary breast cancer patients
31. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma
32. Association of K-ras mutations with p16 methylation in human colon cancer
33. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: Association with DNA replication error and shorter survival
34. Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer
35. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
36. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
37. Nonparametric estimation from incomplete observations
38. Regression models and life tables
39. Free DNA in the serum of cancer patients and the effect of therapy
40. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease
41. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer
42. Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis
43. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer
44. Predicting lung cancer by detecting aberrant promoter methylation in sputum
45. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: Diagnostic utility and prognostic significance
46. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: Follow-up study and prognostic significance